NCT07150221Enrolling By InvitationNot Applicable
Post-Market Clinical Follow-Up Study of the Vivacit-E Vitamin E Highly Crosslinked Polyethylene HXLPE Elevated Liners in Primary THA- A Retrospective Enrollment/Prospective Follow-Up Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Enrolling By Invitation
- Sponsor
- Zimmer Biomet
- Enrollment
- 52
- Locations
- 1
- Primary Endpoint
- Survival of the Implant System via Adverse Events
Study Overview
Brief Summary
The main objective of this study is to confirm long-term safety, performance, and clinical benefits of the Vivacit-E Vitamin E HXLPE Elevated Liners when used in primary total hip arthroplasty.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient was 18 years of age or older and skeletally mature at the time of surgery
- •Patient qualified for and underwent surgical procedure with a Vivacit-E Vitamin E HXLPE Elevated Liner to treat one of the following indications in primary THA:
- •Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis
- •Protrusio acetabuli
- •Traumatic arthritis
- •Slipped capital epiphysis
- •Fused hip
- •Fracture of the pelvis
- •Diastrophic variant
- •Patient underwent surgical procedure 10 years (+ no maximum/- 182 days) prior to date of study consent
- •Patient is will and able to sign IRB approved Informed Consent Form or provide verbal consent
Exclusion Criteria
- •Off label use or not according to the approved IFU at the time of surgery
- •Patient presented with any of the following at the time of the surgical procedure:
- •Osteoradionecrosis
- •Neuromuscular compromise, vascular deficiency or other conditions in the affected limb that may lead to inadequate skeletal fixation
- •Systemic or local infection
- •Revision procedure where other treatment or devices have failed*
- •Patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent
- •Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions
- •For the purpose of this clinical study; a revision procedure refers to a procedure in which the prior procedure on the ipsilateral hip utilized a similar approach (i.e., primary total hip arthoplasty)
Outcomes
Primary Outcomes
Survival of the Implant System via Adverse Events
Time Frame: 10 years
The primary endpoint is defined by the survival of the implant system at 10 years post-operative, which is based on removal of the study device and will be determined using the Kaplan Meier method. The safety of the study device will be assessed by monitoring the frequency and incidence of adverse events.
Secondary Outcomes
- Pain and functional performance measured by the Oxford Hip Score(10 years)
- Subject quality-of-life measured by the EQ-5D-5L(10 Years)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Not Applicable
Avenir® Cemented Hip Stem - PMCFPrimary OsteoarthritisPost-Traumatic Osteoarthritis of HipFemoral Neck FracturesFemoral Head NecrosisSequelae From Previous Hip SurgeryOsteotomiesCongenital Hip DysplasiaNCT03396224Zimmer Biomet100
Terminated
Not Applicable
Post Market Clinical Follow-up Study on da Vinci® Robotic-assisted Prophylactic Nipple Sparing Mastectomy With Breast ReconstructionProphylactic Nipple Sparing Mastectomy (NSM)NCT05251285Intuitive Surgical7
Active, not recruiting
Not Applicable
Essilor® Stellest® Lenses Multicentre European Study (SLOMES)MyopiaNCT06263946Essilor International150
Unknown
Not Applicable
G7 Freedom Constrained Vivacit-E LinersOsteoarthritis, HipNon-Union FractureTrochanteric FracturesFemoral Neck FracturesRheumatoid ArthritisDislocation, HipAvascular NecrosisNCT05587244Zimmer Biomet202
Recruiting
Not Applicable
Performance and Safety Assessment of SPRING THREAD® Elastic Tensor Thread in Patients with Mild to Moderate Facial Ptosis.PtosisPtosis, MildNCT057460781st SurgiConcept99